Trials / Completed
CompletedNCT04241458
A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 706321 in Healthy Male and Female Subjects (Doubleblind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 703621 | BI 703621 |
| DRUG | Placebo | Placebo |
| DRUG | Midazolam | Midazolam |
Timeline
- Start date
- 2020-01-30
- Primary completion
- 2020-11-24
- Completion
- 2020-11-24
- First posted
- 2020-01-27
- Last updated
- 2025-08-24
- Results posted
- 2025-08-24
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04241458. Inclusion in this directory is not an endorsement.